| 6 min read
There are vastly more possible drug-like molecules than any chemist could ever screen. Here is how generative models are actually being used to search that space, and where the approach still runs into hard limits.
| 6 min read
Central nervous system drug design lives or dies on brain penetration, and AI now predicts it well.
| 6 min read
Every ADMET model has a confidence interval; few teams have a rule for when to act on it.Articles
| 6 min read
AI drug-drug interaction models are sophisticated enough to shape candidate choices, within limits.
| 7 min read
AI toxicity models catch real safety liabilities, but off-target biology still slips past them.
| 6 min read
Metabolic liability drops promising compounds early, and machine learning is changing how that call gets made.
| 8 min read
Machine learning flags ADMET liabilities earlier, but knowing when to trust it still matters most.
| 8 min read
Antibody drug discovery poses a different set of AI problems than small molecules. Here is what is actually working for biologics, and how far it is from designing an antibody from scratch.
| 7 min read
Lead optimization is where most drug programs grind through thousands of analogues. AI is not replacing that chemistry, but it is changing how candidates are chosen and prioritized.
| 7 min read
The diffusion model revolution behind AI image generation has a direct parallel in molecular design. Here is how it works and how far the generated molecules are from being drugs.
| 7 min read
Screening scales fast, but confirmed binding still lags far behind the predictions.
| 7 min read
Machine learning ranks targets fast, but only genetics and bench experiments confirm they actually work.
